Advertisement
XOM vs XRAY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is XOM is a Buy and XRAY is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
XOM’s FA Score shows that 2 FA rating(s) are green whileXRAY’s FA Score has 1 green FA rating(s).
- XOM’s FA Score: 2 green, 3 red.
- XRAY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
XOM’s TA Score shows that 4 TA indicator(s) are bullish while XRAY’s TA Score has 6 bullish TA indicator(s).
- XOM’s TA Score: 4 bullish, 6 bearish.
- XRAY’s TA Score: 6 bullish, 3 bearish.
Price Growth
XOM (@Integrated Oil) experienced а -1.74% price change this week, while XRAY (@Pharmaceuticals: Other) price change was +8.47% for the same time period.
The average weekly price growth across all stocks in the @Integrated Oil industry was -1.17%. For the same industry, the average monthly price growth was -5.44%, and the average quarterly price growth was +21.82%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +5.72%. For the same industry, the average monthly price growth was +3.90%, and the average quarterly price growth was -5.44%.
Reported Earning Dates
XOM is expected to report earnings on Jul 24, 2026.
XRAY is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Integrated Oil (-1.17% weekly)Integrated oil companies are involved across nearly the entire oil value chain – from upstream operations like exploration and production, to downstream functions of refining and marketing. Exxon Mobil Corporation, Chevron Corporation and BP are major integrated oil companies. Their bottom lines’ response to crude oil prices could depend on the proportion of upstream vs. downstream businesses; for example, if a company has substantial downstream business, the adverse impact on their upstream business due to falling crude prices could be mitigated by benefits to its downstream business.
@Pharmaceuticals: Other (+5.72% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| XOM | XRAY | XOM / XRAY | |
| Capitalization | 564B | 2.17B | 26,015% |
| EBITDA | 64.4B | -127M | -50,709% |
| Gain YTD | 14.589 | -3.675 | -397% |
| P/E Ratio | 23.31 | N/A | - |
| Revenue | 326B | 3.68B | 8,856% |
| Total Cash | 8.44B | 190M | 4,439% |
| Total Debt | 47.7B | 2.33B | 2,046% |
XOM | XRAY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 58 | 42 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 46 Fair valued | 2 Undervalued | |
PROFIT vs RISK RATING 1..100 | 17 | 100 | |
SMR RATING 1..100 | 72 | 98 | |
PRICE GROWTH RATING 1..100 | 58 | 58 | |
P/E GROWTH RATING 1..100 | 17 | 83 | |
SEASONALITY SCORE 1..100 | 65 | 20 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XRAY's Valuation (2) in the Medical Specialties industry is somewhat better than the same rating for XOM (46) in the Integrated Oil industry. This means that XRAY’s stock grew somewhat faster than XOM’s over the last 12 months.
XOM's Profit vs Risk Rating (17) in the Integrated Oil industry is significantly better than the same rating for XRAY (100) in the Medical Specialties industry. This means that XOM’s stock grew significantly faster than XRAY’s over the last 12 months.
XOM's SMR Rating (72) in the Integrated Oil industry is in the same range as XRAY (98) in the Medical Specialties industry. This means that XOM’s stock grew similarly to XRAY’s over the last 12 months.
XOM's Price Growth Rating (58) in the Integrated Oil industry is in the same range as XRAY (58) in the Medical Specialties industry. This means that XOM’s stock grew similarly to XRAY’s over the last 12 months.
XOM's P/E Growth Rating (17) in the Integrated Oil industry is significantly better than the same rating for XRAY (83) in the Medical Specialties industry. This means that XOM’s stock grew significantly faster than XRAY’s over the last 12 months.
| XOM | XRAY | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 59% | 6 days ago 59% |
| Stochastic ODDS (%) | 1 day ago 73% | 1 day ago 77% |
| Momentum ODDS (%) | 1 day ago 58% | 1 day ago 52% |
| MACD ODDS (%) | 1 day ago 45% | 1 day ago 48% |
| TrendWeek ODDS (%) | 1 day ago 45% | 1 day ago 59% |
| TrendMonth ODDS (%) | 1 day ago 46% | 1 day ago 59% |
| Advances ODDS (%) | 8 days ago 61% | 5 days ago 55% |
| Declines ODDS (%) | 1 day ago 45% | 28 days ago 74% |
| BollingerBands ODDS (%) | 1 day ago 67% | 1 day ago 85% |
| Aroon ODDS (%) | 1 day ago 40% | 1 day ago 50% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ARKG | 42.36 | 0.93 | +2.24% |
| ARK Genomic Revolution ETF | |||
| FLAG | 27.28 | N/A | N/A |
| Global X S&P 500 U.S. Market Leaders Top 50 ETF | |||
| SPBC | 46.39 | N/A | N/A |
| Simplify US Equity PLUS Bitcoin Stgy ETF | |||
| CPHY | 51.56 | N/A | N/A |
| F/m Compoundr High Yield Bond ETF | |||
| USNZ | 46.82 | -0.58 | -1.22% |
| Xtrackers Net Zero Pwy Par Alg US Eq ETF | |||
XOM and
Correlation & Price change
A.I.dvisor indicates that over the last year, XOM has been closely correlated with CVX. These tickers have moved in lockstep 83% of the time. This A.I.-generated data suggests there is a high statistical probability that if XOM jumps, then CVX could also see price increases.
| Ticker / NAME | Correlation To XOM | 1D Price Change % | ||
|---|---|---|---|---|
| XOM | 100% | -0.35% | ||
| CVX - XOM | 83% Closely correlated | -1.51% | ||
| EQNR - XOM | 70% Closely correlated | +0.48% | ||
| CRGY - XOM | 69% Closely correlated | -1.19% | ||
| BP - XOM | 68% Closely correlated | +0.59% | ||
| CVE - XOM | 68% Closely correlated | +0.73% | ||
More | ||||
XRAY and
Correlation & Price change
A.I.dvisor indicates that over the last year, XRAY has been loosely correlated with NVST. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if XRAY jumps, then NVST could also see price increases.
| Ticker / NAME | Correlation To XRAY | 1D Price Change % | ||
|---|---|---|---|---|
| XRAY | 100% | N/A | ||
| NVST - XRAY | 62% Loosely correlated | +0.22% | ||
| ALGN - XRAY | 51% Loosely correlated | N/A | ||
| QDEL - XRAY | 50% Loosely correlated | N/A | ||
| KIDS - XRAY | 48% Loosely correlated | N/A | ||
| BAX - XRAY | 47% Loosely correlated | -0.09% | ||
More | ||||